ASCO Annual Meeting brings you the highlights from the ASCO Annual Meeting. Refer back to this page often to read the latest news from ASCO, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings.

Meeting News

Gene assay predicts renal cell carcinoma relapse

September 20, 2017
CHICAGO – The Recurrence Score, a tool used to predict risk of relapse in renal cell carcinoma, appears effective in high-risk disease…
Meeting News

Gene assay facilitates personalizing extended endocrine therapy

August 28, 2017
CHICAGO – The Breast Cancer Index, a gene assay that provides information about a patient’s risk for distant recurrence as well as the…
Meeting News

Guest Commentary: Low testosterone, other side effects surface years after testicular cancer treatment

August 22, 2017
In this guest commentary, Ajay Singla, MD, of the department of urology at Massachusetts General Hospital, reviews the potential
Meeting News

Radiation benefits patients with lung cancer who relapse after chemotherapy

August 11, 2017
CHICAGO – Thoracic radiation used in combination with chemotherapy may improve survival outcomes compared with chemotherapy alone in patients…
Meeting NewsVideo

VIDEO: Gefitinib may ‘change the paradigm’ to treat lung cancer

August 10, 2017
CHICAGO — Lecia V. Sequist, MD, MPH, the Mary B. Saltonstall Endowed Chair in Oncology at Massachusetts General Hospital and
Meeting News

Guest Commentary: Resistance to androgen-targeting agents highlights unmet need in prostate cancer

August 10, 2017
In this guest commentary, Leonard J. Appleman, MD, PhD, of the division of hematology/oncology at the University of Pittsburgh
Meeting News

Resuming treatment with cabazitaxel provides ‘option’ in advanced prostate cancer

August 8, 2017
CHICAGO – Retreatment with cabazitaxel demonstrated encouraging activity and acceptable toxicity when used in combination with a new hormonal…
Meeting News

Shorter duration of androgen deprivation therapy reduces side effects in prostate cancer

August 7, 2017
CHICAGO – Reducing the duration of androgen deprivation therapy from 36 to 18 months improved quality of life without affecting survival…
Meeting News

Palbociclib fails to reach response rate in lung cancer

August 6, 2017
CHICAGO — Palbociclib failed to reach a pre-specified response rate in patients with stage IV squamous cell lung cancer, according to results…
Meeting News

Ado-trastuzumab emtansine offers effective alternative as first-line therapy in breast cancer

August 3, 2017
CHICAGO — First-line therapy with ado-trastuzumab emtansine improved OS and reduced grade 3 and higher adverse events in patients with…